GB0424024D0 - Tissue-specific endothelial membrane proteins - Google Patents
Tissue-specific endothelial membrane proteinsInfo
- Publication number
- GB0424024D0 GB0424024D0 GBGB0424024.8A GB0424024A GB0424024D0 GB 0424024 D0 GB0424024 D0 GB 0424024D0 GB 0424024 A GB0424024 A GB 0424024A GB 0424024 D0 GB0424024 D0 GB 0424024D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- tissue
- membrane proteins
- specific endothelial
- endothelial membrane
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 210000004954 endothelial membrane Anatomy 0.000 title 1
- 210000001519 tissue Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36945202P | 2002-04-01 | 2002-04-01 | |
| PCT/US2003/010195 WO2003084469A2 (en) | 2002-04-01 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0424024D0 true GB0424024D0 (en) | 2004-12-01 |
Family
ID=28791952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0423854A Withdrawn GB2403222A (en) | 2002-04-01 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
| GBGB0424024.8A Ceased GB0424024D0 (en) | 2002-04-01 | 2004-10-29 | Tissue-specific endothelial membrane proteins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0423854A Withdrawn GB2403222A (en) | 2002-04-01 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2003222185A1 (en) |
| CA (1) | CA2481334A1 (en) |
| GB (2) | GB2403222A (en) |
| WO (1) | WO2003084469A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| FR2883873B1 (en) | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | AGE INHIBITORS |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| EP2434287A1 (en) | 2006-09-25 | 2012-03-28 | Universiteit Maastricht | Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
| FI20075278A0 (en) | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Novel completely human anti-VAP-1 monoclonal antibodies |
| CA2698357C (en) | 2007-09-04 | 2017-06-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| CA2925862A1 (en) | 2013-10-01 | 2015-04-09 | Glaxosmithkline Intellectual Property Development Limited | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
| CN112535726B (en) * | 2019-09-05 | 2023-09-12 | 南京安吉生物科技有限公司 | Tumor marker AQUAPRIN 2 protein and application thereof |
| KR20250089521A (en) * | 2022-10-14 | 2025-06-18 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Compositions and methods for targeted delivery of therapeutic agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| DE69328430T2 (en) * | 1992-07-27 | 2001-01-25 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | TARGETED LIPOSOME TO THE BLOOD BRAIN CABINET |
| ATE384736T1 (en) * | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | SUB-CELLULAR TARGETING OF THERAPEUTIC PROTEINS |
-
2003
- 2003-03-31 GB GB0423854A patent/GB2403222A/en not_active Withdrawn
- 2003-03-31 WO PCT/US2003/010195 patent/WO2003084469A2/en not_active Ceased
- 2003-03-31 AU AU2003222185A patent/AU2003222185A1/en not_active Abandoned
- 2003-03-31 CA CA002481334A patent/CA2481334A1/en not_active Abandoned
-
2004
- 2004-10-29 GB GBGB0424024.8A patent/GB0424024D0/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB2403222A (en) | 2004-12-29 |
| AU2003222185A1 (en) | 2003-10-20 |
| CA2481334A1 (en) | 2003-10-16 |
| WO2003084469A3 (en) | 2004-06-10 |
| GB0423854D0 (en) | 2004-12-01 |
| WO2003084469A2 (en) | 2003-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1399215A4 (en) | Tissue-specific endothelial membrane proteins | |
| GB0208331D0 (en) | Proteins | |
| GB0209884D0 (en) | Proteins | |
| GB0423854D0 (en) | Tissue-specific endothelial membrane proteins | |
| GB0220770D0 (en) | Proteins | |
| EP1487874A4 (en) | Falp proteins | |
| GB0212067D0 (en) | Proteins | |
| AU2003270055A8 (en) | Neurotransmission-associated proteins | |
| EP1559786A4 (en) | Mast cell-derived membrane proteins | |
| GB0311108D0 (en) | Proteins | |
| GB0125093D0 (en) | Multimeric proteins | |
| AU2003300785A8 (en) | Carbohydrate-associated proteins | |
| IL169260A0 (en) | Il-8 -like proteins | |
| GB0206684D0 (en) | Novel proteins | |
| GB0224781D0 (en) | Endothelial cell protein | |
| AU2003295760A8 (en) | Organelle-associated proteins | |
| GB0216757D0 (en) | Proteins | |
| AU2003236908A8 (en) | Proteins | |
| GB0211903D0 (en) | Proteins | |
| GB0024770D0 (en) | Multimeric proteins | |
| GB0201606D0 (en) | Proteins | |
| GB0208707D0 (en) | Proteins | |
| GB0218039D0 (en) | Proteins | |
| GB0219053D0 (en) | Proteins | |
| GB0220768D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |